These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25725419)

  • 1. Radical Prostatectomy Findings in Men on Active Surveillance: Variable Findings Dependent on Reason for Surgery and Entry Criteria.
    Matoso A; Hassan O; Petrozzino F; Rao BV; Carter HB; Epstein JI
    J Urol; 2015 Sep; 194(3):685-9. PubMed ID: 25725419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.
    Reese AC; Landis P; Han M; Epstein JI; Carter HB
    J Urol; 2013 Dec; 190(6):2033-8. PubMed ID: 23680308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
    Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
    J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
    Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
    J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
    Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
    J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
    Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
    J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
    Newcomb LF; Thompson IM; Boyer HD; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Ellis WJ; Fazli L; Feng Z; Gleave ME; Kunju P; Lance RS; McKenney JK; Meng MV; Nicolas MM; Sanda MG; Simko J; So A; Tretiakova MS; Troyer DA; True LD; Vakar-Lopez F; Virgin J; Wagner AA; Wei JT; Zheng Y; Nelson PS; Lin DW;
    J Urol; 2016 Feb; 195(2):313-20. PubMed ID: 26327354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance.
    Satkunasivam R; Kulkarni GS; Zlotta AR; Kalnin R; Trachtenberg J; Fleshner NE; Hamilton RJ; Jewett MA; Finelli A
    J Urol; 2013 Jul; 190(1):91-5. PubMed ID: 23321581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
    Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
    Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.
    Hussein AA; Welty CJ; Ameli N; Cowan JE; Leapman M; Porten SP; Shinohara K; Carroll PR
    J Urol; 2015 Jul; 194(1):85-90. PubMed ID: 25623742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological features after radical prostatectomy in potential candidates for active monitoring.
    Griffin CR; Yu X; Loeb S; Desireddi VN; Han M; Graif T; Catalona WJ
    J Urol; 2007 Sep; 178(3 Pt 1):860-3; discussion 863. PubMed ID: 17631347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.
    Carter HB; Walsh PC; Landis P; Epstein JI
    J Urol; 2002 Mar; 167(3):1231-4. PubMed ID: 11832703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?
    Chen DJ; Falzarano SM; McKenney JK; Przybycin CG; Reynolds JP; Roma A; Jones JS; Stephenson A; Klein E; Magi-Galluzzi C
    BJU Int; 2015 Aug; 116(2):220-9. PubMed ID: 25060664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
    Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M
    BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
    Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
    Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.